Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval

By Denny Jacob

Bristol Myers Squibb disclosed that the U.S. Food and Drug Administration granted accelerated approval of Augtyro.

The biopharmaceutical product developer said the approval is based on results from a Phase 1/2 study which evaluated Augtyro in adult patients with neurotrophic tyrosine receptor kinase positive solid tumors.

The treatment's approval applies to adult and pediatric patients ages 12 years and up with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion, among other factors.

Write to Denny Jacob at [e-mail]

(END) Dow Jones Newswires

06-13-24 1723ET